Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1 beta, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-alpha, which hallmarks the most severe clinical cases. 'Repurposing' immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients.
The Rheumatology Drugs for COVID-19 Management : Which and When? / F. Atzeni, I. Masala, J. Rodriguez-Carrio, R. Rios-Garces, E. Gerratana, L. La Corte, M. Giallanza, V. Nucera, A. Riva, G. Espinosa, R. Cervera. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:4(2021), pp. 783.1-783.20. [10.3390/jcm10040783]
The Rheumatology Drugs for COVID-19 Management : Which and When?
A. Riva;
2021
Abstract
Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1 beta, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-alpha, which hallmarks the most severe clinical cases. 'Repurposing' immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients.File | Dimensione | Formato | |
---|---|---|---|
jcm-10-00783-v3.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
629.07 kB
Formato
Adobe PDF
|
629.07 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.